sotalol has been researched along with Recrudescence in 86 studies
Sotalol: An adrenergic beta-antagonist that is used in the treatment of life-threatening arrhythmias.
sotalol : A sulfonamide that is N-phenylmethanesulfonamide in which the phenyl group is substituted at position 4 by a 1-hydroxy-2-(isopropylamino)ethyl group. It has both beta-adrenoreceptor blocking (Vaughan Williams Class II) and cardiac action potential duration prolongation (Vaughan Williams Class III) antiarrhythmic properties. It is used (usually as the hydrochloride salt) for the management of ventricular and supraventricular arrhythmias.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Participants receiving sotalol or dofetilide for atrial or ventricular arrhythmias were randomized to receive magnesium l-lactate (504 mg elemental magnesium daily, Niche Pharmaceuticals, Roanoke, TX) or placebo for 48 hours." | 9.12 | An evaluation of the impact of oral magnesium lactate on the corrected QT interval of patients receiving sotalol or dofetilide to prevent atrial or ventricular tachyarrhythmia recurrence. ( Coleman, CI; Guertin, D; Henyan, NN; Kluger, J; McBride, BF; Min, B; Silver, BB; White, CM, 2006) |
| "This prospective, randomized, single-blinded, placebo-controlled study compared the efficacy and safety of sotalol and propafenone when used for long-term prevention of atrial fibrillation." | 9.11 | Sotalol versus propafenone for long-term maintenance of normal sinus rhythm in patients with recurrent symptomatic atrial fibrillation. ( Chlouverakis, GI; Hamilos, ME; Igoumenidis, NE; Klapsinos, NC; Kochiadakis, GE; Tzerakis, PG; Vardas, PE, 2004) |
| "This study was performed to evaluate, using a randomized double-blind, placebo-controlled protocol, the long-term efficacy and safety of propafenone and sotalol in maintaining sinus rhythm after conversion of recurrent symptomatic atrial fibrillation (AF)." | 9.09 | Long-term efficacy and safety of propafenone and sotalol for the maintenance of sinus rhythm after conversion of recurrent symptomatic atrial fibrillation. ( Bellandi, F; Dabizzi, RP; Frascarelli, F; Giovannini, T; Leoncini, M; Maioli, M; Simonetti, I, 2001) |
| "To compare the efficacy and safety of sotalol and quinidine after conversion of atrial fibrillation (AF) of <6 months, a prospective multicenter trial enrolled 121 patients who were randomized to receive dl-sotalol (160 to 320 mg/day, 58 patients) or quinidine sulfate (600 to 800 mg/day, 63 patients)." | 9.09 | Efficacy and safety of sotalol versus quinidine for the maintenance of sinus rhythm after conversion of atrial fibrillation. SOCESP Investigators. The Cardiology Society of São Paulo. ( de Paola, AA; Veloso, HH, 1999) |
| "The purpose of the study was to compare the efficacy and safety of sotalol and bisoprolol in the maintenance of sinus rhythm after electrical cardioversion of atrial fibrillation." | 9.09 | Maintenance of sinus rhythm after electrical cardioversion of persistent atrial fibrillation; sotalol vs bisoprolol. ( Alt, EU; Lehmann, G; Ndrepepa, G; Plewan, A; Schmitt, C; Schömig, A; Schreieck, J, 2001) |
| "This randomized study compared the efficacy and safety of amiodarone, propafenone and sotalol in the prevention of atrial fibrillation." | 9.09 | Amiodarone, sotalol, or propafenone in atrial fibrillation: which is preferred to maintain normal sinus rhythm? ( Chrysostomakis, SI; Igoumenidis, NE; Kaleboubas, MD; Kochiadakis, GE; Marketou, ME; Mavrakis, HE; Vardas, PE, 2000) |
| "To assess and compare the safety and efficacy of amiodarone and sotalol in the treatment of patients with recurrent symptomatic atrial fibrillation." | 9.09 | Low dose amiodarone and sotalol in the treatment of recurrent, symptomatic atrial fibrillation: a comparative, placebo controlled study. ( Igoumenidis, NE; Kaleboubas, MD; Kochiadakis, GE; Marketou, ME; Simantirakis, EN; Vardas, PE, 2000) |
| "In patients with persistent atrial fibrillation, oral treatment with magnesium alone or as an adjuvant to sotalol, does not influence the recurrence rate of atrial fibrillation after elective cardioversion." | 9.09 | The effect of oral magnesium, alone or as an adjuvant to sotalol, after cardioversion in patients with persistent atrial fibrillation. ( Darpö, B; Frick, M; Ostergren, J; Rosenqvist, M, 2000) |
| "To compare the safety and efficacy of amiodarone and sotalol in the treatment of patients with recurrent symptomatic atrial fibrillation (AF), 70 patients were entered into a randomized, double-blind study." | 9.08 | Low-dose amiodarone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. ( Igoumenidis, NE; Kanoupakis, EM; Kochiadakis, GE; Marketou, ME; Solomou, MC; Vardas, PE, 1998) |
| "We performed a randomized, double-blind, placebo-controled, parallel-group comparison study of the efficacy and safety of sotalol in the prophylaxis of paroxysmal supraventricular tachyarrhythmias (PSVTs) (including paroxysmal atrial fibrillation and paroxysmal reentrant SVTs)." | 9.08 | Multicenter comparative study of the efficacy and safety of sotalol in the prophylactic treatment of patients with paroxysmal supraventricular tachyarrhythmias. ( Anderson, K; Joseph, SP; Joy, M; Wanless, RS, 1997) |
| "Aim of the present study was to assess the efficacy and safety of flecainide (F) and sotalol (S) for the prevention of recurrences of paroxysmal atrial fibrillation (PAF)." | 9.08 | [A comparison between flecainide and sotalol in the prevention of recurrences of paroxysmal atrial fibrillation]. ( Burattini, M; Carunchio, A; Ceci, V; Fera, MS; Galati, A; Greco, G; Mazza, A, 1995) |
| "To analyze the recurrences of atrial fibrillation in patients treated with sotalol or quinidine." | 9.08 | [Analysis of atrial fibrillation recurrence during therapy with sotalol or quinidine. Researchers of +SOCESP]. ( de Paola, AA; Veloso, HH, 1998) |
| "This study investigated the hemodynamic effects of oral sotalol during both sinus rhythm and paroxysmal atrial fibrillation." | 9.07 | Hemodynamic effects of oral sotalol during both sinus rhythm and atrial fibrillation. ( Alboni, P; Chioin, R; Fucà, G; Paparella, N; Pedini, I; Razzolini, R; Scarfò, S, 1993) |
| "This open, parallel-group study compares quinidine and sotalol treatment for maintenance of sinus rhythm after direct current conversion of patients with chronic atrial fibrillation." | 9.06 | Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. ( Edvardsson, N; Juul-Möller, S; Rehnqvist-Ahlberg, N, 1990) |
| "In a multicentre double-blind randomised study, the effect of sotalol 320 mg once daily was compared with that of placebo in patients surviving an acute myocardial infarction." | 9.05 | Controlled trial of sotalol for one year after myocardial infarction. ( Jackson, FS; Julian, DG; Prescott, RJ; Szekely, P, 1982) |
| "We carried out a double-blind, randomized study, based at The Academic Department of Cardiology in Newcastle upon Tyne, to compare the effect of sotalol 320 mg once daily with that of placebo in patients from 20 hospitals who survived an acute myocardial infarction." | 9.05 | A controlled trial of sotalol for 1 year after myocardial infarction. ( Jackson, FS; Julian, DG; Prescott, RJ; Szekely, P, 1983) |
| " Antiarrhythmic therapy with sotalol at 240 mg/day was started, and after 48 h the patient experienced several episodes of sustained torsade de pointes, dramatic marked QT interval prolongation and negative T wave, in absence of overt cardiac disease, renal failure, electrolyte abnormalities or baseline QT interval prolongation." | 7.73 | Sustained torsade de pointes occurring early during oral sotalol therapy for atrial fibrillation recurrence prophylaxis in a patient without heart disease. ( Boldini, A; Brentana, L; D'Aloia, A; Dei Cas, L; Faggiano, P; Pedrinazzi, C; Procopio, R, 2005) |
| "To study the incidence and mode of onset of early reinitiation of atrial fibrillation (ERAF) following successful internal cardioversion of chronic atrial fibrillation, and to determine the effects of sotalol in the prevention of ERAF." | 7.70 | Incidence and modes of onset of early reinitiation of atrial fibrillation after successful internal cardioversion, and its prevention by intravenous sotalol. ( Ayers, GM; Lau, CP; Tse, HF, 1999) |
| "This study was undertaken to assess the effects of sotalol on the transthoracic cardioversion energy requirement for chronic atrial fibrillation (AF) and on the atrial electrograms during AF recorded by two basket electrodes." | 7.70 | Intravenous sotalol decreases transthoracic cardioversion energy requirement for chronic atrial fibrillation in humans: assessment of the electrophysiological effects by biatrial basket electrodes. ( Huang, SK; Lai, LP; Lien, WP; Lin, JL; Tseng, YZ, 2000) |
| "The safety and efficacy of oral sotalol, an investigational beta-adrenergic blocker with class III antiarrhythmic drug properties, were examined in a multicenter study in 236 patients with sustained ventricular tachyarrhythmias." | 7.68 | Safety and efficacy of sotalol in patients with drug-refractory sustained ventricular tachyarrhythmias. ( Dunnington, CS; Kehoe, RF; Mattioni, TA; Spangenberg, RB; Yu, G; Zheutlin, TA, 1990) |
| "To assess the antiarrhythmic efficacy of oral d,l-sotalol, 68 patients with sustained monomorphic ventricular tachycardia (SMVT) (n = 62) or ventricular fibrillation (VF) (n = 6) were studied by programmed ventricular stimulation (PVS)." | 7.68 | Sotalol in patients with life-threatening ventricular tachyarrhythmias. ( Klein, H; Lichtlen, P; Trappe, HJ, 1990) |
| "A 69 year old woman was treated with sotalol (320 mg daily) for intermittent atrial fibrillation." | 7.68 | Sotalol-induced torsade de pointes: management with magnesium infusion. ( Arstall, MA; Hii, JT; Horowitz, JD; Lehman, RG, 1992) |
| "The electrophysiologic effects and antiarrhythmic efficacy of oral sotalol were investigated in 42 patients with coronary artery disease and prior myocardial infarction who presented with ventricular tachycardia (VT), ventricular fibrillation (VF) or syncope." | 7.67 | Usefulness of sotalol in suppressing ventricular tachycardia or ventricular fibrillation in patients with healed myocardial infarcts. ( Finkelstein, D; Garan, H; Kuchar, DL; McComb, J; McGovern, BA; Rottman, JN; Ruskin, JN; Venditti, FJ, 1989) |
| "The effects of oral sotalol were compared with the findings obtained in the baseline study of a group of 26 consecutive patients with sustained monomorphic ventricular tachycardia or ventricular fibrillation and inducible ventricular tachycardia." | 7.67 | Low-dose oral sotalol for monomorphic ventricular tachycardia: effects during programmed electrical stimulation and follow-up. ( Clement, DL; Jordaens, LJ; Palmer, A, 1989) |
| "Sotalol was initiated." | 6.73 | Bifocal versus unifocal right atrial pacing under plasma level controlled sotalol to prevent atrial fibrillation in patients with symptomatic sinus bradycardia and paroxysmal atrial fibrillation. ( Butter, C; Gerhardt, L; Helms, S; Schlegl, M; Stockburger, M, 2007) |
| "Sotalol was given for extended therapy to 22 of 29 patients with frequent (greater than or equal to 30/hour) complex premature ventricular complexes (PVCs) who had participated in a short-term study of sotalol vs placebo." | 6.66 | Long-term experience with sotalol in the treatment of complex ventricular arrhythmias. ( Anastasiou-Nana, MI; Anderson, JL; Askins, JC; Gilbert, EM; Menlove, RL; Nanas, JN, 1987) |
| "Recurrence was noted to occur within 2 months of therapy." | 5.46 | Use of flecainide in combination antiarrhythmic therapy in patients with arrhythmogenic right ventricular cardiomyopathy. ( Ermakov, S; Gerstenfeld, EP; Scheinman, MM; Svetlichnaya, Y, 2017) |
| "Oral sotalol treatment was started after unsuccessful DC cardioversion and given at least 7 days before renewed cardioversion." | 5.33 | Rate of conversion and recurrence after sotalol treatment in patients with direct current-refractory atrial fibrillation. ( Frick, M; Nergärdh, A; Nordlander, R, 2006) |
| "Univariate predictors for recurrence included coronary artery disease (p < 0." | 5.30 | Patient characteristics and underlying heart disease as predictors of recurrent atrial fibrillation after internal and external cardioversion in patients treated with oral sotalol. ( Alt, E; Ammer, R; Ayers, GM; Lehmann, G; Pasquantonio, J; Pütter, K; Schömig, A, 1997) |
| " Conversion to sinus rhythm was achieved in 16 out of 22 hemodynamically stable children with a dosage of 4." | 5.30 | Sotalol for atrial tachycardias after surgery for congenital heart disease. ( Beaufort-Krol, GC; Bink-Boelkens, MT, 1997) |
| "Sotalol was withdrawn in 11 patients because of continued inducibility of ventricular tachycardia at the time of follow-up electrophysiologic study." | 5.28 | Clinical experience with sotalol in patients with drug-refractory ventricular arrhythmias. ( Ellis, T; Lebsack, C; Mead, RH; Ruder, MA; Smith, NA; Winkle, RA, 1989) |
| "Participants receiving sotalol or dofetilide for atrial or ventricular arrhythmias were randomized to receive magnesium l-lactate (504 mg elemental magnesium daily, Niche Pharmaceuticals, Roanoke, TX) or placebo for 48 hours." | 5.12 | An evaluation of the impact of oral magnesium lactate on the corrected QT interval of patients receiving sotalol or dofetilide to prevent atrial or ventricular tachyarrhythmia recurrence. ( Coleman, CI; Guertin, D; Henyan, NN; Kluger, J; McBride, BF; Min, B; Silver, BB; White, CM, 2006) |
| "This prospective, randomized, single-blinded, placebo-controlled study compared the efficacy and safety of sotalol and propafenone when used for long-term prevention of atrial fibrillation." | 5.11 | Sotalol versus propafenone for long-term maintenance of normal sinus rhythm in patients with recurrent symptomatic atrial fibrillation. ( Chlouverakis, GI; Hamilos, ME; Igoumenidis, NE; Klapsinos, NC; Kochiadakis, GE; Tzerakis, PG; Vardas, PE, 2004) |
| "This study was performed to evaluate, using a randomized double-blind, placebo-controlled protocol, the long-term efficacy and safety of propafenone and sotalol in maintaining sinus rhythm after conversion of recurrent symptomatic atrial fibrillation (AF)." | 5.09 | Long-term efficacy and safety of propafenone and sotalol for the maintenance of sinus rhythm after conversion of recurrent symptomatic atrial fibrillation. ( Bellandi, F; Dabizzi, RP; Frascarelli, F; Giovannini, T; Leoncini, M; Maioli, M; Simonetti, I, 2001) |
| "To compare the efficacy and safety of sotalol and quinidine after conversion of atrial fibrillation (AF) of <6 months, a prospective multicenter trial enrolled 121 patients who were randomized to receive dl-sotalol (160 to 320 mg/day, 58 patients) or quinidine sulfate (600 to 800 mg/day, 63 patients)." | 5.09 | Efficacy and safety of sotalol versus quinidine for the maintenance of sinus rhythm after conversion of atrial fibrillation. SOCESP Investigators. The Cardiology Society of São Paulo. ( de Paola, AA; Veloso, HH, 1999) |
| "In patients with persistent atrial fibrillation, oral treatment with magnesium alone or as an adjuvant to sotalol, does not influence the recurrence rate of atrial fibrillation after elective cardioversion." | 5.09 | The effect of oral magnesium, alone or as an adjuvant to sotalol, after cardioversion in patients with persistent atrial fibrillation. ( Darpö, B; Frick, M; Ostergren, J; Rosenqvist, M, 2000) |
| "To assess and compare the safety and efficacy of amiodarone and sotalol in the treatment of patients with recurrent symptomatic atrial fibrillation." | 5.09 | Low dose amiodarone and sotalol in the treatment of recurrent, symptomatic atrial fibrillation: a comparative, placebo controlled study. ( Igoumenidis, NE; Kaleboubas, MD; Kochiadakis, GE; Marketou, ME; Simantirakis, EN; Vardas, PE, 2000) |
| "This randomized study compared the efficacy and safety of amiodarone, propafenone and sotalol in the prevention of atrial fibrillation." | 5.09 | Amiodarone, sotalol, or propafenone in atrial fibrillation: which is preferred to maintain normal sinus rhythm? ( Chrysostomakis, SI; Igoumenidis, NE; Kaleboubas, MD; Kochiadakis, GE; Marketou, ME; Mavrakis, HE; Vardas, PE, 2000) |
| "The purpose of the study was to compare the efficacy and safety of sotalol and bisoprolol in the maintenance of sinus rhythm after electrical cardioversion of atrial fibrillation." | 5.09 | Maintenance of sinus rhythm after electrical cardioversion of persistent atrial fibrillation; sotalol vs bisoprolol. ( Alt, EU; Lehmann, G; Ndrepepa, G; Plewan, A; Schmitt, C; Schömig, A; Schreieck, J, 2001) |
| "We performed a randomized, double-blind, placebo-controled, parallel-group comparison study of the efficacy and safety of sotalol in the prophylaxis of paroxysmal supraventricular tachyarrhythmias (PSVTs) (including paroxysmal atrial fibrillation and paroxysmal reentrant SVTs)." | 5.08 | Multicenter comparative study of the efficacy and safety of sotalol in the prophylactic treatment of patients with paroxysmal supraventricular tachyarrhythmias. ( Anderson, K; Joseph, SP; Joy, M; Wanless, RS, 1997) |
| "To analyze the recurrences of atrial fibrillation in patients treated with sotalol or quinidine." | 5.08 | [Analysis of atrial fibrillation recurrence during therapy with sotalol or quinidine. Researchers of +SOCESP]. ( de Paola, AA; Veloso, HH, 1998) |
| "Aim of the present study was to assess the efficacy and safety of flecainide (F) and sotalol (S) for the prevention of recurrences of paroxysmal atrial fibrillation (PAF)." | 5.08 | [A comparison between flecainide and sotalol in the prevention of recurrences of paroxysmal atrial fibrillation]. ( Burattini, M; Carunchio, A; Ceci, V; Fera, MS; Galati, A; Greco, G; Mazza, A, 1995) |
| "To compare the safety and efficacy of amiodarone and sotalol in the treatment of patients with recurrent symptomatic atrial fibrillation (AF), 70 patients were entered into a randomized, double-blind study." | 5.08 | Low-dose amiodarone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. ( Igoumenidis, NE; Kanoupakis, EM; Kochiadakis, GE; Marketou, ME; Solomou, MC; Vardas, PE, 1998) |
| "This study investigated the hemodynamic effects of oral sotalol during both sinus rhythm and paroxysmal atrial fibrillation." | 5.07 | Hemodynamic effects of oral sotalol during both sinus rhythm and atrial fibrillation. ( Alboni, P; Chioin, R; Fucà, G; Paparella, N; Pedini, I; Razzolini, R; Scarfò, S, 1993) |
| "This open, parallel-group study compares quinidine and sotalol treatment for maintenance of sinus rhythm after direct current conversion of patients with chronic atrial fibrillation." | 5.06 | Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. ( Edvardsson, N; Juul-Möller, S; Rehnqvist-Ahlberg, N, 1990) |
| "The relative safety and efficacy of intravenous administration of adenosine, lignocaine, disopyramide, flecainide, and sotalol for termination of stable, induced ventricular tachycardia was assessed in serial trials." | 5.06 | Relative efficacy and safety of intravenous drugs for termination of sustained ventricular tachycardia. ( Camm, AJ; Garratt, CJ; Griffith, MJ; Linker, NJ; Ward, DE, 1990) |
| "We carried out a double-blind, randomized study, based at The Academic Department of Cardiology in Newcastle upon Tyne, to compare the effect of sotalol 320 mg once daily with that of placebo in patients from 20 hospitals who survived an acute myocardial infarction." | 5.05 | A controlled trial of sotalol for 1 year after myocardial infarction. ( Jackson, FS; Julian, DG; Prescott, RJ; Szekely, P, 1983) |
| "Recently completed Beta-Blocker Heart Attack Trial in which propranolol was administered to patients following an acute myocardial infarction resulted in a 26% decrease in total mortality and a 23% decrease in total coronary events in the propranolol-treated patients as compared to the placebo patients during the average follow-up of 25 months." | 5.05 | The Beta-Blocker Heart Attack Trial in perspective. ( Goldstein, S, 1983) |
| "In a multicentre double-blind randomised study, the effect of sotalol 320 mg once daily was compared with that of placebo in patients surviving an acute myocardial infarction." | 5.05 | Controlled trial of sotalol for one year after myocardial infarction. ( Jackson, FS; Julian, DG; Prescott, RJ; Szekely, P, 1982) |
| "Among the drugs recommended to prevent recurrences of atrial fibrillation after external electric shock, antiarrhythmic agents of classes Ia (quinidine, disopyramide), Ic (cibenzoline, flecainide, propafenone) and III (sotalol) seem to have the same effectiveness in maintaining the sinus rhythm in about 50 percent of the cases after 6 months and one year." | 4.78 | [Antiarrhythmic treatment after reduction of atrial fibrillation by external shock]. ( Brechenmacher, C; Chauvin, M; Koenig, A; Theolade, R, 1993) |
| "Retrospective analysis of 2 double-blind, parallel-group trials (EURIDIS [European Trial in Atrial Fibrillation or Flutter Patients Receiving Dronedarone for the Maintenance of Sinus Rhythm] and ADONIS [American-Australian-African Trial With Dronedarone in Atrial Fibrillation or Flutter Patients for the Maintenance of Sinus Rhythm]) comparing the efficacy and safety of dronedarone with placebo over 12 months." | 3.80 | Efficacy and safety of dronedarone in patients previously treated with other antiarrhythmic agents. ( Aliot, EM; Capucci, A; Connolly, S; Crijns, HJ; Guerra, F; Hohnloser, SH; Kowey, PR; Radzik, D; Roy, D, 2014) |
| " Antiarrhythmic therapy with sotalol at 240 mg/day was started, and after 48 h the patient experienced several episodes of sustained torsade de pointes, dramatic marked QT interval prolongation and negative T wave, in absence of overt cardiac disease, renal failure, electrolyte abnormalities or baseline QT interval prolongation." | 3.73 | Sustained torsade de pointes occurring early during oral sotalol therapy for atrial fibrillation recurrence prophylaxis in a patient without heart disease. ( Boldini, A; Brentana, L; D'Aloia, A; Dei Cas, L; Faggiano, P; Pedrinazzi, C; Procopio, R, 2005) |
| "To study the incidence and mode of onset of early reinitiation of atrial fibrillation (ERAF) following successful internal cardioversion of chronic atrial fibrillation, and to determine the effects of sotalol in the prevention of ERAF." | 3.70 | Incidence and modes of onset of early reinitiation of atrial fibrillation after successful internal cardioversion, and its prevention by intravenous sotalol. ( Ayers, GM; Lau, CP; Tse, HF, 1999) |
| "This study was undertaken to assess the effects of sotalol on the transthoracic cardioversion energy requirement for chronic atrial fibrillation (AF) and on the atrial electrograms during AF recorded by two basket electrodes." | 3.70 | Intravenous sotalol decreases transthoracic cardioversion energy requirement for chronic atrial fibrillation in humans: assessment of the electrophysiological effects by biatrial basket electrodes. ( Huang, SK; Lai, LP; Lien, WP; Lin, JL; Tseng, YZ, 2000) |
| "A 69 year old woman was treated with sotalol (320 mg daily) for intermittent atrial fibrillation." | 3.68 | Sotalol-induced torsade de pointes: management with magnesium infusion. ( Arstall, MA; Hii, JT; Horowitz, JD; Lehman, RG, 1992) |
| "The safety and efficacy of oral sotalol, an investigational beta-adrenergic blocker with class III antiarrhythmic drug properties, were examined in a multicenter study in 236 patients with sustained ventricular tachyarrhythmias." | 3.68 | Safety and efficacy of sotalol in patients with drug-refractory sustained ventricular tachyarrhythmias. ( Dunnington, CS; Kehoe, RF; Mattioni, TA; Spangenberg, RB; Yu, G; Zheutlin, TA, 1990) |
| "One hundred nine patients with recurrent episodes of symptomatic atrial fibrillation or flutter, or both, who had failed one to five previous antiarrhythmic drug trials were treated with propafenone and, subsequently, sotalol if atrial fibrillation recurred." | 3.68 | Therapy of refractory symptomatic atrial fibrillation and atrial flutter: a staged care approach with new antiarrhythmic drugs. ( Antman, EM; Beamer, AD; Cantillon, C; Friedman, PL; McGowan, N, 1990) |
| "To assess the antiarrhythmic efficacy of oral d,l-sotalol, 68 patients with sustained monomorphic ventricular tachycardia (SMVT) (n = 62) or ventricular fibrillation (VF) (n = 6) were studied by programmed ventricular stimulation (PVS)." | 3.68 | Sotalol in patients with life-threatening ventricular tachyarrhythmias. ( Klein, H; Lichtlen, P; Trappe, HJ, 1990) |
| "The electrophysiologic effects and antiarrhythmic efficacy of oral sotalol were investigated in 42 patients with coronary artery disease and prior myocardial infarction who presented with ventricular tachycardia (VT), ventricular fibrillation (VF) or syncope." | 3.67 | Usefulness of sotalol in suppressing ventricular tachycardia or ventricular fibrillation in patients with healed myocardial infarcts. ( Finkelstein, D; Garan, H; Kuchar, DL; McComb, J; McGovern, BA; Rottman, JN; Ruskin, JN; Venditti, FJ, 1989) |
| "The effects of oral sotalol were compared with the findings obtained in the baseline study of a group of 26 consecutive patients with sustained monomorphic ventricular tachycardia or ventricular fibrillation and inducible ventricular tachycardia." | 3.67 | Low-dose oral sotalol for monomorphic ventricular tachycardia: effects during programmed electrical stimulation and follow-up. ( Clement, DL; Jordaens, LJ; Palmer, A, 1989) |
| "Standardized treatment of fetal tachyarrhythmia has not been established." | 2.90 | Antenatal Therapy for Fetal Supraventricular Tachyarrhythmias: Multicenter Trial. ( Hagiwara, A; Hamasaki, T; Horigome, H; Ikeda, T; Inamura, N; Kato, H; Katsuragi, S; Kawataki, M; Maeno, Y; Miyoshi, T; Nii, M; Sago, H; Sakaguchi, H; Shimizu, W; Shiraishi, I; Taketazu, M; Ueda, K; Yamamoto, H; Yasukochi, S; Yoda, H, 2019) |
| "Persistent AF and hypertension are independent risk factors for late AF recurrence after pulmonary vein isolation." | 2.79 | Does a blanking period after pulmonary vein isolation impact long-term results? Results after 55 months of follow-up. ( Balsam, P; Kiliszek, M; Kochanowski, J; Koźluk, E; Lodziński, P; Opolski, G; Piątkowska, A; Piątkowski, R; Scisło, P, 2014) |
| "Sotalol was initiated." | 2.73 | Bifocal versus unifocal right atrial pacing under plasma level controlled sotalol to prevent atrial fibrillation in patients with symptomatic sinus bradycardia and paroxysmal atrial fibrillation. ( Butter, C; Gerhardt, L; Helms, S; Schlegl, M; Stockburger, M, 2007) |
| " Despite careful precautions, serious proarrhythmias, the major limiting side effect of dofetilide, still occurred during long-term follow-up." | 2.73 | Observations on the safety and effectiveness of dofetilide in patients with paroxysmal atrial fibrillation and normal left ventricular function. ( Bauman, JL; Kehoe, RF; Leal, S; Mykytsey, A; Razminia, M; Saleem, M; Wang, T; Zheutlin, T, 2007) |
| "However, patients with no symptomatic recurrences of AF had higher scores at 3 months on measures of global well-being than those with recurrences in the first 3 months (7." | 2.70 | Quality of life improves with treatment in the Canadian Trial of Atrial Fibrillation. ( Connolly, SJ; Dorian, P; Green, M; Newman, D; Paquette, M; Roy, D; Talajic, M, 2002) |
| "The indication to treat symptomatic paroxysmal atrial fibrillation is discussed controversely." | 2.69 | [Medicamentous prevention of symptomatic paroxysmal atrial fibrillation/flutter onset. Goals and design of the SOPAT Study. Executive committee of the investigators representing trial physicians]. ( Koch, HP; Lüderitz, B; Meinertz, T; Patten, M; Sonntag, F, 1999) |
| "In case of PAF recurrence pts withdrew from the study." | 2.68 | [Comparison of anti-arrhythmic therapy guided by the transesophageal electropharmacologic test and emperic therapy in the prophylaxis of atrial fibrillation recurrence]. ( Burattini, M; Carunchio, A; Ceci, V; Coletta, C; Fera, MS; Galati, A; Mazza, A, 1997) |
| "Sotalol was discontinued because of adverse effects in 42 (8." | 2.67 | Safety and efficacy of oral sotalol for sustained ventricular tachyarrhythmias refractory to other antiarrhythmic agents. ( Dunnington, C; Ezri, MD; Kehoe, RF; Lueken, M; MacNeil, DJ; Nazari, J; Spangenberg, RB; Zheutlin, TA, 1993) |
| "486 patients with documented ventricular tachycardia or resuscitated sudden death were randomized to EPS (n = 242) or HM (n = 244) and underwent serial drug testing with up to six antiarrhythmics; in the EPS limb a drug efficacy prediction was achieved in 108 patients (45%), compared to 188 (77%) in the HM limb (P < 0." | 2.67 | Comparative efficacy of sotalol and class I antiarrhythmic agents in patients with ventricular tachycardia or fibrillation: results of the Electrophysiology Study Versus Electrocardiographic Monitoring (ESVEM) Trial. ( Klein, RC, 1993) |
| "This study assessed the efficacy of the combination of sotalol and either quinidine or procainamide in preventing sustained ventricular tachycardia inducibility and recurrence and prospectively evaluated the ability of the drug combination to prevent ventricular tachycardia recurrence when the arrhythmia remained inducible but was modified." | 2.67 | Sotalol and type IA drugs in combination prevent recurrence of sustained ventricular tachycardia. ( Berman, N; Dorian, P; Hardy, J; Mitchell, J; Newman, D, 1993) |
| "Sotalol was significantly more efficacious in preventing recurrences, arrhythmic mortality, cardiac mortality, and total mortality than the other agents and it was better tolerated." | 2.67 | Results of Holter ECG guided therapy for ventricular arrhythmias: the ESVEM trial. ( Lazzara, R, 1994) |
| "Sotalol was given for extended therapy to 22 of 29 patients with frequent (greater than or equal to 30/hour) complex premature ventricular complexes (PVCs) who had participated in a short-term study of sotalol vs placebo." | 2.66 | Long-term experience with sotalol in the treatment of complex ventricular arrhythmias. ( Anastasiou-Nana, MI; Anderson, JL; Askins, JC; Gilbert, EM; Menlove, RL; Nanas, JN, 1987) |
| "Atrial flutter is most often arising from a macroreentry circuit in the right atrium or around scar tissue in case or previous cardiothoracic surgery." | 2.43 | [Atrial flutter and fibrillation]. ( Scharf, C, 2005) |
| "With a probability of success of 90%, a recurrence rate of 5% to 15%, and few complications, catheter ablation emerges as the best treatment of recurrent, symptomatic flutter." | 2.41 | Management of atrial flutter. ( Aass, H; Kongsgaard, E, 2000) |
| "Sotalol's ability to suppress ventricular ectopy is similar to that of class I agents and better than that of standard beta-blockers." | 2.40 | Sotalol: An important new antiarrhythmic. ( Anderson, JL; Prystowsky, EN, 1999) |
| "Patients with symptomatic ventricular tachycardia, ventricular fibrillation, or aborted sudden cardiac death remain at high risk for arrhythmia recurrence." | 2.40 | Drugs versus devices in controlling ventricular tachycardia, ventricular fibrillation, and recurrent cardiac arrest. ( Borggrefe, M; Breithardt, G; Eckardt, L; Haverkamp, W, 1997) |
| "Recurrence was noted to occur within 2 months of therapy." | 1.46 | Use of flecainide in combination antiarrhythmic therapy in patients with arrhythmogenic right ventricular cardiomyopathy. ( Ermakov, S; Gerstenfeld, EP; Scheinman, MM; Svetlichnaya, Y, 2017) |
| "Adenosine has been well studied as a mainstay treatment, but the methods of adenosine administration have not been very well delineated." | 1.38 | Intraosseous infusion is unreliable for adenosine delivery in the treatment of supraventricular tachycardia. ( Goodman, IS; Lu, CJ, 2012) |
| "Time to persistent arrhythmia recurrence was compared between first and multiple DCCV, and the effect of age, gender, presence of heart disease, left atrial size, fractional shortening, arrhythmia duration, anti-arrhythmic drug therapy (AAD) and other concomitant cardiac medication was evaluated using the Kaplan-Meier method and Cox's Proportional-hazards model." | 1.36 | First time and repeat cardioversion of atrial tachyarrhythmias - a comparison of outcomes. ( Arya, A; Boodhoo, L; Bordoli, G; Cheek, E; Large, J; Lloyd, GW; Mitchell, A; Patel, NR; Pugh, P; Silberbauer, JS; Sulke, AN; Taggu, W; Vrahimides, J, 2010) |
| "Sotalol was administered to 57 patients, and its efficacy was assessed by EPS." | 1.33 | Electrophysiologic study-guided therapy with sotalol for life-threatening ventricular tachyarrhythmias. ( Aizawa, Y; Chinushi, M; Fujita, S; Furushima, H; Hirono, T; Hosaka, Y; Kato, K; Komura, S; Sugiura, H; Tanabe, Y; Washizuka, T; Watanabe, H, 2005) |
| "Oral sotalol treatment was started after unsuccessful DC cardioversion and given at least 7 days before renewed cardioversion." | 1.33 | Rate of conversion and recurrence after sotalol treatment in patients with direct current-refractory atrial fibrillation. ( Frick, M; Nergärdh, A; Nordlander, R, 2006) |
| "The difference in the time course of AF recurrence in patients with ERAF from those with long AF duration suggests distinct arrhythmogenic mechanisms." | 1.32 | Clinical predictors and time course of arrhythmia recurrence in patients with early reinitiation of atrial fibrillation after successful internal cardioversion. ( Lau, CP; Tse, HF, 2003) |
| "Average follow up at first AF recurrence was 18." | 1.31 | Atrial fibrillation recurrence after internal cardioversion: prognostic importance of electrophysiological parameters. ( Bacchi Reggiani, L; Bartolotti, M; Biffi, M; Boriani, G; Branzi, A; Zannoli, R, 2002) |
| " The mortality rate in this study was 19% (4 of 21 fetuses; 3 had SVT and 1 had AF); 3 deaths occurred just days after the initiation of sotalol therapy, and 1 occurred after a dosage increase." | 1.31 | Sotalol in the treatment of fetal dysrhythmias. ( Kapusta, L; Kleinman, CS; Meijboom, EJ; Michon, MM; Oudijk, MA; Stoutenbeek, P; Visser, GH, 2000) |
| "Thirty patients with VT/VF (age: 57+/-11 years, 20 patients with coronary heart disease, 7 patients with no structural heart disease, 3 with others) and reproducible induction of VT/VF (28 patients VT, two patients VF) in a baseline PVS, were suppressible with sotalol (mean dosage 395+/-137 mg) in a subsequent PVS." | 1.30 | Long-term reproducibility of electrophysiologically guided therapy with sotalol in patients with ventricular tachyarrhythmias. ( Bosch, RF; Kühlkamp, V; Mermi, J; Mewis, C; Seipel, L, 1999) |
| " Conversion to sinus rhythm was achieved in 16 out of 22 hemodynamically stable children with a dosage of 4." | 1.30 | Sotalol for atrial tachycardias after surgery for congenital heart disease. ( Beaufort-Krol, GC; Bink-Boelkens, MT, 1997) |
| "Univariate predictors for recurrence included coronary artery disease (p < 0." | 1.30 | Patient characteristics and underlying heart disease as predictors of recurrent atrial fibrillation after internal and external cardioversion in patients treated with oral sotalol. ( Alt, E; Ammer, R; Ayers, GM; Lehmann, G; Pasquantonio, J; Pütter, K; Schömig, A, 1997) |
| "Recurrence is common, although antiarrhythmic drugs often effectively decrease the number and duration of recurrent AF episodes." | 1.30 | Factors influencing long term persistence of sinus rhythm after a first electrical cardioversion for atrial fibrillation. ( Duytschaever, M; Haerynck, F; Jordaens, L; Tavernier, R, 1998) |
| "A patient with preexistent left bundle branch block and spontaneous ventricular tachycardia based upon the bundle branch reentry mechanism underwent electrophysiological testing for the evaluation of sotalol drug efficacy." | 1.28 | Inadvertent catheter-induced right bundle branch block in a patient with preexistent left bundle branch block and recurrent macroreentrant ventricular tachycardia. ( Gössinger, HD; Leitha, T; Mösslacher, H; Siostrzonek, P; Wagner, L, 1989) |
| "Sotalol was withdrawn in 11 patients because of continued inducibility of ventricular tachycardia at the time of follow-up electrophysiologic study." | 1.28 | Clinical experience with sotalol in patients with drug-refractory ventricular arrhythmias. ( Ellis, T; Lebsack, C; Mead, RH; Ruder, MA; Smith, NA; Winkle, RA, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (12.79) | 18.7374 |
| 1990's | 31 (36.05) | 18.2507 |
| 2000's | 35 (40.70) | 29.6817 |
| 2010's | 8 (9.30) | 24.3611 |
| 2020's | 1 (1.16) | 2.80 |
| Authors | Studies |
|---|---|
| Miyoshi, T | 1 |
| Maeno, Y | 1 |
| Hamasaki, T | 1 |
| Inamura, N | 1 |
| Yasukochi, S | 1 |
| Kawataki, M | 1 |
| Horigome, H | 1 |
| Yoda, H | 1 |
| Taketazu, M | 1 |
| Nii, M | 1 |
| Hagiwara, A | 1 |
| Kato, H | 1 |
| Shimizu, W | 1 |
| Shiraishi, I | 1 |
| Sakaguchi, H | 1 |
| Ueda, K | 1 |
| Katsuragi, S | 1 |
| Yamamoto, H | 1 |
| Sago, H | 1 |
| Ikeda, T | 1 |
| Capponi, G | 1 |
| Belli, G | 1 |
| Giovannini, M | 1 |
| Remaschi, G | 1 |
| Brambilla, A | 1 |
| Vannuccini, F | 1 |
| Favilli, S | 1 |
| Porcedda, G | 1 |
| De Simone, L | 1 |
| Lodziński, P | 1 |
| Kiliszek, M | 1 |
| Koźluk, E | 1 |
| Piątkowska, A | 1 |
| Balsam, P | 1 |
| Kochanowski, J | 1 |
| Scisło, P | 1 |
| Piątkowski, R | 1 |
| Opolski, G | 1 |
| Guerra, F | 1 |
| Hohnloser, SH | 1 |
| Kowey, PR | 1 |
| Crijns, HJ | 2 |
| Aliot, EM | 1 |
| Radzik, D | 1 |
| Roy, D | 2 |
| Connolly, S | 1 |
| Capucci, A | 1 |
| Qin, D | 1 |
| Leef, G | 1 |
| Alam, MB | 1 |
| Rattan, R | 1 |
| Munir, MB | 1 |
| Patel, D | 1 |
| Khattak, F | 1 |
| Adelstein, E | 1 |
| Jain, SK | 1 |
| Saba, S | 1 |
| Ermakov, S | 1 |
| Gerstenfeld, EP | 1 |
| Svetlichnaya, Y | 1 |
| Scheinman, MM | 1 |
| Andersen, SS | 1 |
| Hansen, ML | 1 |
| Gislason, GH | 1 |
| Folke, F | 1 |
| Schramm, TK | 1 |
| Fosbøl, E | 1 |
| Sørensen, R | 1 |
| Rasmussen, S | 1 |
| Abildstrøm, SZ | 1 |
| Madsen, M | 1 |
| Køber, L | 1 |
| Torp-Pedersen, C | 1 |
| Zakrzewska-Koperska, J | 1 |
| Urbanek, P | 1 |
| Szufladowicz, E | 1 |
| Bodalski, R | 1 |
| Szumowski, Ł | 1 |
| Maryniak, A | 1 |
| Walczak, F | 1 |
| Shimada, YJ | 1 |
| Sato, K | 1 |
| Hanon, S | 1 |
| Schweitzer, P | 1 |
| Venkataraman, G | 1 |
| Strickberger, SA | 1 |
| Arya, A | 1 |
| Silberbauer, JS | 1 |
| Vrahimides, J | 1 |
| Cheek, E | 1 |
| Mitchell, A | 1 |
| Boodhoo, L | 1 |
| Pugh, P | 1 |
| Large, J | 1 |
| Bordoli, G | 1 |
| Taggu, W | 1 |
| Lloyd, GW | 1 |
| Patel, NR | 1 |
| Sulke, AN | 1 |
| Goodman, IS | 1 |
| Lu, CJ | 1 |
| Kettering, K | 1 |
| Mewis, C | 2 |
| Dörnberger, V | 1 |
| Vonthein, R | 1 |
| Bosch, RF | 2 |
| Kühlkamp, V | 2 |
| Friberg, J | 1 |
| Gadsbøll, N | 1 |
| Tse, HF | 3 |
| Lau, CP | 3 |
| Lee, JK | 2 |
| Klein, GJ | 2 |
| Krahn, AD | 2 |
| Yee, R | 2 |
| Zarnke, K | 2 |
| Simpson, C | 2 |
| Skanes, A | 2 |
| Dorian, P | 3 |
| Mangat, I | 1 |
| Kochiadakis, GE | 4 |
| Igoumenidis, NE | 4 |
| Hamilos, ME | 1 |
| Tzerakis, PG | 1 |
| Klapsinos, NC | 1 |
| Chlouverakis, GI | 1 |
| Vardas, PE | 4 |
| Watanabe, H | 1 |
| Chinushi, M | 1 |
| Washizuka, T | 1 |
| Sugiura, H | 1 |
| Hirono, T | 1 |
| Komura, S | 1 |
| Hosaka, Y | 1 |
| Tanabe, Y | 1 |
| Furushima, H | 1 |
| Fujita, S | 1 |
| Kato, K | 1 |
| Aizawa, Y | 1 |
| D'Aloia, A | 1 |
| Faggiano, P | 1 |
| Brentana, L | 1 |
| Boldini, A | 1 |
| Pedrinazzi, C | 1 |
| Procopio, R | 1 |
| Dei Cas, L | 1 |
| Scharf, C | 1 |
| Gorenek, B | 1 |
| Cavusoglu, Y | 1 |
| Goktekin, O | 1 |
| Birdane, A | 1 |
| Kudaiberdieva, G | 1 |
| Ata, N | 1 |
| Unalir, A | 1 |
| Timuralp, B | 1 |
| Nergärdh, A | 1 |
| Nordlander, R | 1 |
| Frick, M | 2 |
| Brunckhorst, CB | 1 |
| McBride, BF | 1 |
| Min, B | 1 |
| Kluger, J | 1 |
| Guertin, D | 1 |
| Henyan, NN | 1 |
| Coleman, CI | 1 |
| Silver, BB | 1 |
| White, CM | 1 |
| Mykytsey, A | 1 |
| Bauman, JL | 1 |
| Razminia, M | 1 |
| Zheutlin, T | 1 |
| Wang, T | 1 |
| Saleem, M | 1 |
| Leal, S | 1 |
| Kehoe, RF | 3 |
| Stockburger, M | 1 |
| Gerhardt, L | 1 |
| Helms, S | 1 |
| Schlegl, M | 1 |
| Butter, C | 1 |
| Julian, DG | 2 |
| Prescott, RJ | 2 |
| Jackson, FS | 2 |
| Szekely, P | 2 |
| Staessen, J | 1 |
| Bulpitt, C | 1 |
| Cattaert, A | 1 |
| Fagard, R | 1 |
| Vanhees, L | 1 |
| Amery, A | 1 |
| Goldstein, S | 1 |
| Rizos, I | 1 |
| Senges, J | 1 |
| Jauernig, R | 1 |
| Lengfelder, W | 1 |
| Czygan, E | 1 |
| Brachmann, J | 1 |
| Kübler, W | 1 |
| Lazzara, R | 1 |
| Carunchio, A | 2 |
| Fera, MS | 2 |
| Mazza, A | 2 |
| Burattini, M | 2 |
| Greco, G | 1 |
| Galati, A | 2 |
| Ceci, V | 2 |
| Reimold, SC | 2 |
| Lamas, GA | 1 |
| Cantillon, CO | 2 |
| Antman, EM | 3 |
| Alboni, P | 1 |
| Razzolini, R | 1 |
| Scarfò, S | 1 |
| Paparella, N | 1 |
| Fucà, G | 1 |
| Pedini, I | 1 |
| Chioin, R | 1 |
| Klein, RC | 1 |
| Koenig, A | 1 |
| Theolade, R | 1 |
| Chauvin, M | 1 |
| Brechenmacher, C | 1 |
| MacNeil, DJ | 1 |
| Zheutlin, TA | 2 |
| Ezri, MD | 1 |
| Nazari, J | 1 |
| Spangenberg, RB | 2 |
| Dunnington, C | 1 |
| Lueken, M | 1 |
| Friedman, PL | 2 |
| Newman, D | 2 |
| Berman, N | 1 |
| Hardy, J | 1 |
| Mitchell, J | 1 |
| Wanless, RS | 1 |
| Anderson, K | 1 |
| Joy, M | 1 |
| Joseph, SP | 1 |
| Coletta, C | 1 |
| Beaufort-Krol, GC | 1 |
| Bink-Boelkens, MT | 1 |
| Alt, E | 1 |
| Ammer, R | 1 |
| Lehmann, G | 2 |
| Pütter, K | 1 |
| Ayers, GM | 3 |
| Pasquantonio, J | 1 |
| Schömig, A | 2 |
| Haverkamp, W | 2 |
| Eckardt, L | 1 |
| Borggrefe, M | 2 |
| Breithardt, G | 2 |
| Duytschaever, M | 1 |
| Haerynck, F | 1 |
| Tavernier, R | 1 |
| Jordaens, L | 1 |
| Marketou, ME | 3 |
| Solomou, MC | 1 |
| Kanoupakis, EM | 1 |
| Veloso, HH | 2 |
| de Paola, AA | 2 |
| Anderson, JL | 2 |
| Prystowsky, EN | 1 |
| Patten, M | 1 |
| Koch, HP | 1 |
| Sonntag, F | 1 |
| Lüderitz, B | 2 |
| Meinertz, T | 1 |
| Mermi, J | 1 |
| Seipel, L | 1 |
| Lai, LP | 2 |
| Lin, JL | 2 |
| Lien, WP | 2 |
| Tseng, YZ | 2 |
| Huang, SK | 2 |
| Lewalter, T | 1 |
| Oudijk, MA | 1 |
| Michon, MM | 1 |
| Kleinman, CS | 1 |
| Kapusta, L | 1 |
| Stoutenbeek, P | 1 |
| Visser, GH | 1 |
| Meijboom, EJ | 1 |
| Darpö, B | 1 |
| Ostergren, J | 1 |
| Rosenqvist, M | 1 |
| Kongsgaard, E | 1 |
| Aass, H | 1 |
| Kaleboubas, MD | 2 |
| Simantirakis, EN | 1 |
| Cooley, R | 1 |
| Akhtar, M | 1 |
| Sra, J | 1 |
| Spindler, B | 1 |
| Chrysostomakis, SI | 1 |
| Mavrakis, HE | 1 |
| Barbosa, EC | 1 |
| Barbosa, PR | 1 |
| Ginefra, P | 1 |
| de Souza Bomfim, A | 1 |
| Boghossian, SH | 1 |
| da Rocha, PJ | 1 |
| Filho, FM | 1 |
| Plewan, A | 1 |
| Ndrepepa, G | 1 |
| Schreieck, J | 1 |
| Alt, EU | 1 |
| Schmitt, C | 1 |
| Bellandi, F | 1 |
| Simonetti, I | 1 |
| Leoncini, M | 1 |
| Frascarelli, F | 1 |
| Giovannini, T | 1 |
| Maioli, M | 1 |
| Dabizzi, RP | 1 |
| Price, JF | 1 |
| Kertesz, NJ | 1 |
| Snyder, CS | 1 |
| Friedman, RA | 1 |
| Fenrich, AL | 1 |
| Fetsch, T | 1 |
| Biffi, M | 1 |
| Boriani, G | 1 |
| Bartolotti, M | 1 |
| Bacchi Reggiani, L | 1 |
| Zannoli, R | 1 |
| Branzi, A | 1 |
| Paquette, M | 1 |
| Green, M | 1 |
| Connolly, SJ | 1 |
| Talajic, M | 1 |
| Shenasa, M | 1 |
| Hindricks, G | 1 |
| Arstall, MA | 1 |
| Hii, JT | 1 |
| Lehman, RG | 1 |
| Horowitz, JD | 1 |
| Van Gelder, IC | 1 |
| Van Gilst, WH | 1 |
| Hillege, H | 1 |
| Gosselink, AM | 1 |
| Lie, KI | 1 |
| Griffith, MJ | 1 |
| Linker, NJ | 1 |
| Garratt, CJ | 1 |
| Ward, DE | 1 |
| Camm, AJ | 1 |
| Juul-Möller, S | 1 |
| Edvardsson, N | 1 |
| Rehnqvist-Ahlberg, N | 1 |
| Trappe, HJ | 1 |
| Klein, H | 1 |
| Lichtlen, P | 1 |
| Dunnington, CS | 1 |
| Mattioni, TA | 1 |
| Yu, G | 1 |
| Beamer, AD | 1 |
| Cantillon, C | 1 |
| McGowan, N | 1 |
| Gössinger, HD | 1 |
| Siostrzonek, P | 1 |
| Wagner, L | 1 |
| Leitha, T | 1 |
| Mösslacher, H | 1 |
| Jordaens, LJ | 1 |
| Palmer, A | 1 |
| Clement, DL | 1 |
| Kuchar, DL | 1 |
| Garan, H | 1 |
| Venditti, FJ | 1 |
| Finkelstein, D | 1 |
| Rottman, JN | 1 |
| McComb, J | 1 |
| McGovern, BA | 1 |
| Ruskin, JN | 1 |
| Ruder, MA | 1 |
| Ellis, T | 1 |
| Lebsack, C | 1 |
| Mead, RH | 1 |
| Smith, NA | 1 |
| Winkle, RA | 1 |
| Bowman, E | 1 |
| Paes, BA | 1 |
| Way, RC | 1 |
| Anastasiou-Nana, MI | 1 |
| Askins, JC | 1 |
| Gilbert, EM | 1 |
| Nanas, JN | 1 |
| Menlove, RL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pilot Randomized Trial With Flecainide in ARVC Patients[NCT03685149] | Phase 2 | 23 participants (Actual) | Interventional | 2019-07-31 | Completed | ||
| [NCT00000492] | Phase 3 | 0 participants | Interventional | 1977-09-30 | Completed | ||
| [NCT00000518] | Phase 3 | 0 participants | Interventional | 1985-07-31 | Completed | ||
| [NCT00224341] | Phase 4 | 360 participants | Interventional | 2003-11-30 | Recruiting | ||
| Subclinical Postoperative Atrial Fibrillation[NCT02522364] | 150 participants (Anticipated) | Interventional | 2015-08-31 | Recruiting | |||
| Safety Assessment for Sotalol Protocol in Outpatient Unit[NCT05418036] | Phase 4 | 110 participants (Anticipated) | Interventional | 2020-10-26 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for sotalol and Recrudescence
| Article | Year |
|---|---|
[Atrial flutter and fibrillation].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Amiodarone; Anti-Arrhythmia | 2005 |
[Antiarrhythmic treatment after reduction of atrial fibrillation by external shock].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Combined Modality Therapy; Disopyramide; El | 1993 |
Drugs versus devices in controlling ventricular tachycardia, ventricular fibrillation, and recurrent cardiac arrest.
Topics: Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; Heart Arrest; Humans; Randomized Co | 1997 |
Sotalol: An important new antiarrhythmic.
Topics: Action Potentials; Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Atrial Fibrillation; Defibri | 1999 |
Management of atrial flutter.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Flutter; Catheter Ablation; Electrophysiologic Techniques, C | 2000 |
Is primary antiarrhythmic drug therapy for ventricular arrhythmias obsolete?
Topics: Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implantable; Humans; Ran | 1999 |
How to evaluate class III antiarrhythmic drug efficacy clinically: the benefits and shortcomings of the invasive approach.
Topics: Amiodarone; Anti-Arrhythmia Agents; Drug Evaluation; Electric Stimulation; Electrocardiography, Ambu | 1992 |
40 trials available for sotalol and Recrudescence
| Article | Year |
|---|---|
Antenatal Therapy for Fetal Supraventricular Tachyarrhythmias: Multicenter Trial.
Topics: Administration, Oral; Adult; Anti-Arrhythmia Agents; Atrial Flutter; Cesarean Section; Digoxin; Fema | 2019 |
Does a blanking period after pulmonary vein isolation impact long-term results? Results after 55 months of follow-up.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Chi-Square Distri | 2014 |
Efficacy of metoprolol and sotalol in the prevention of recurrences of sustained ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator.
Topics: Defibrillators, Implantable; Female; Humans; Male; Metoprolol; Middle Aged; Prospective Studies; Rec | 2002 |
Intracardiac low-energy versus transthoracic high-energy direct-current cardioversion of atrial fibrillation: a randomised comparison.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Biomarkers; Creatine Kinase; Electric | 2003 |
Rate-control versus conversion strategy in postoperative atrial fibrillation: trial design and pilot study results.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmia, Sinus; Atrial Fib | 2003 |
Quality of life variables in the selection of rate versus rhythm control in patients with atrial fibrillation: observations from the Canadian Trial of Atrial Fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Health Status Indicators; Humans; Propafeno | 2003 |
Sotalol versus propafenone for long-term maintenance of normal sinus rhythm in patients with recurrent symptomatic atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Humans; Male; Middle Aged; Propafenone; P | 2004 |
Amiodarone versus Sotalol and Propafenone for prevention of immediate recurrence of atrial fibrillation after internal cardioversion: importance of P wave analysis.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Female; Humans; Male | 2006 |
An evaluation of the impact of oral magnesium lactate on the corrected QT interval of patients receiving sotalol or dofetilide to prevent atrial or ventricular tachyarrhythmia recurrence.
Topics: Administration, Oral; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Chi-Square Distribution; D | 2006 |
Observations on the safety and effectiveness of dofetilide in patients with paroxysmal atrial fibrillation and normal left ventricular function.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flut | 2007 |
Bifocal versus unifocal right atrial pacing under plasma level controlled sotalol to prevent atrial fibrillation in patients with symptomatic sinus bradycardia and paroxysmal atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Bradycardia; Combined Modality Therapy; Cross-Ove | 2007 |
Controlled trial of sotalol for one year after myocardial infarction.
Topics: Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; | 1982 |
Secondary prevention with beta-adrenoceptor blockers in post-myocardial infarction patients.
Topics: Adrenergic beta-Antagonists; Clinical Trials as Topic; Double-Blind Method; Humans; Metoprolol; Myoc | 1982 |
The Beta-Blocker Heart Attack Trial in perspective.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Arrhythmias, Cardiac; Clinical Trials as Topic; Death, Sud | 1983 |
A controlled trial of sotalol for 1 year after myocardial infarction.
Topics: Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Humans; Middle Aged; Myocardial Infarcti | 1983 |
Results of Holter ECG guided therapy for ventricular arrhythmias: the ESVEM trial.
Topics: Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Death, Sudden, Cardiac; Electrocardiography, Amb | 1994 |
[A comparison between flecainide and sotalol in the prevention of recurrences of paroxysmal atrial fibrillation].
Topics: Adult; Aged; Atrial Fibrillation; Female; Flecainide; Follow-Up Studies; Humans; Male; Middle Aged; | 1995 |
Risk factors for the development of recurrent atrial fibrillation: role of pacing and clinical variables.
Topics: Atrial Fibrillation; Cardiac Pacing, Artificial; Chronic Disease; Female; Heart Atria; Heart Disease | 1995 |
Hemodynamic effects of oral sotalol during both sinus rhythm and atrial fibrillation.
Topics: Administration, Oral; Adult; Aged; Atrial Fibrillation; Cardiac Catheterization; Cardiac Pacing, Art | 1993 |
Comparative efficacy of sotalol and class I antiarrhythmic agents in patients with ventricular tachycardia or fibrillation: results of the Electrophysiology Study Versus Electrocardiographic Monitoring (ESVEM) Trial.
Topics: Actuarial Analysis; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Electrocardiography, Ambulat | 1993 |
Safety and efficacy of oral sotalol for sustained ventricular tachyarrhythmias refractory to other antiarrhythmic agents.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Electrocardiography, Ambul | 1993 |
Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation.
Topics: Aged; Atrial Fibrillation; Electrocardiography, Ambulatory; Female; Follow-Up Studies; Humans; Male; | 1993 |
Sotalol and type IA drugs in combination prevent recurrence of sustained ventricular tachycardia.
Topics: Aged; Cardiac Pacing, Artificial; Drug Therapy, Combination; Electrocardiography; Female; Humans; Ma | 1993 |
Multicenter comparative study of the efficacy and safety of sotalol in the prophylactic treatment of patients with paroxysmal supraventricular tachyarrhythmias.
Topics: Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Double-Blind Method; D | 1997 |
[Comparison of anti-arrhythmic therapy guided by the transesophageal electropharmacologic test and emperic therapy in the prophylaxis of atrial fibrillation recurrence].
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Echocardiography, Transesophageal; Female; Flecainide; | 1997 |
Low-dose amiodarone versus sotalol for suppression of recurrent symptomatic atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Double-Blind Method; Female; Follow-Up Stud | 1998 |
[Analysis of atrial fibrillation recurrence during therapy with sotalol or quinidine. Researchers of +SOCESP].
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Humans; Male; Middle Aged; Quinidi | 1998 |
[Medicamentous prevention of symptomatic paroxysmal atrial fibrillation/flutter onset. Goals and design of the SOPAT Study. Executive committee of the investigators representing trial physicians].
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Dose-Response Relationship, Drug; Doubl | 1999 |
Efficacy and safety of sotalol versus quinidine for the maintenance of sinus rhythm after conversion of atrial fibrillation. SOCESP Investigators. The Cardiology Society of São Paulo.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Chronic Disease; Female; Heart Rate; Human | 1999 |
The effect of oral magnesium, alone or as an adjuvant to sotalol, after cardioversion in patients with persistent atrial fibrillation.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; D | 2000 |
Atrial pacing for suppression of early reinitiation of atrial fibrillation after successful internal cardioversion.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing, Artificial; Electric Count | 2000 |
Low dose amiodarone and sotalol in the treatment of recurrent, symptomatic atrial fibrillation: a comparative, placebo controlled study.
Topics: Aged; Amiodarone; Analysis of Variance; Anti-Arrhythmia Agents; Atrial Fibrillation; Chi-Square Dist | 2000 |
Rate-control versus conversion strategy in postoperative atrial fibrillation: a prospective, randomized pilot study.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgical Procedures; Digoxin; | 2000 |
Amiodarone, sotalol, or propafenone in atrial fibrillation: which is preferred to maintain normal sinus rhythm?
Topics: Administration, Oral; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Heart R | 2000 |
Maintenance of sinus rhythm after electrical cardioversion of persistent atrial fibrillation; sotalol vs bisoprolol.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Atrial Fibrillation; Bisoprolol; Electric Count | 2001 |
Long-term efficacy and safety of propafenone and sotalol for the maintenance of sinus rhythm after conversion of recurrent symptomatic atrial fibrillation.
Topics: Administration, Oral; Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease-Free Surviva | 2001 |
Quality of life improves with treatment in the Canadian Trial of Atrial Fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Canada; Female; Health Status Indicat | 2002 |
Relative efficacy and safety of intravenous drugs for termination of sustained ventricular tachycardia.
Topics: Adenosine; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Clinical Trials as Topic; Disopyramid | 1990 |
Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation.
Topics: Adolescent; Adult; Aged; Arrhythmias, Cardiac; Atrial Fibrillation; Death, Sudden; Dose-Response Rel | 1990 |
Long-term experience with sotalol in the treatment of complex ventricular arrhythmias.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Arrhythmias, Cardiac; Drug Administration Sche | 1987 |
39 other studies available for sotalol and Recrudescence
| Article | Year |
|---|---|
Supraventricular tachycardias in the first year of life: what is the best pharmacological treatment? 24 years of experience in a single centre.
Topics: Action Potentials; Adrenergic beta-Antagonists; Age Factors; Anti-Arrhythmia Agents; Digoxin; Drug T | 2021 |
Efficacy and safety of dronedarone in patients previously treated with other antiarrhythmic agents.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Double-Blind Method; Droned | 2014 |
Comparative effectiveness of antiarrhythmic drugs for rhythm control of atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cohort Studies; Dronedarone; Female; | 2016 |
Use of flecainide in combination antiarrhythmic therapy in patients with arrhythmogenic right ventricular cardiomyopathy.
Topics: Adult; Anti-Arrhythmia Agents; Arrhythmogenic Right Ventricular Dysplasia; Catheter Ablation; Combin | 2017 |
Mortality and reinfarction among patients using different beta-blockers for secondary prevention after a myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Bisoprolol; Female; Humans; Kaplan-Meier Estimate; Male | 2009 |
[Next cardioversion or RF ablation in professional driver with recurrent typical atrial flutter and MAS syndromes].
Topics: Adult; Anti-Arrhythmia Agents; Atrial Flutter; Automobile Driving; Catheter Ablation; Electrocardiog | 2009 |
Termination of recurrent ventricular tachycardia by continuous positive airway pressure ventilation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Carbazoles; Cardiomyopathy, H | 2009 |
Atrial fibrillation degenerates into ventricular fibrillation.
Topics: Adult; Anti-Arrhythmia Agents; Atrial Fibrillation; Combined Modality Therapy; Defibrillators, Impla | 2010 |
First time and repeat cardioversion of atrial tachyarrhythmias - a comparison of outcomes.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Electric Countershock; Female; Humans; Male; Recurrence; R | 2010 |
Intraosseous infusion is unreliable for adenosine delivery in the treatment of supraventricular tachycardia.
Topics: Adenosine; Amiodarone; Catheterization, Central Venous; Combined Modality Therapy; Drug Therapy, Com | 2012 |
Clinical predictors and time course of arrhythmia recurrence in patients with early reinitiation of atrial fibrillation after successful internal cardioversion.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Case-Control Studies; Electric Countershock; Fema | 2003 |
Electrophysiologic study-guided therapy with sotalol for life-threatening ventricular tachyarrhythmias.
Topics: Aged; Analysis of Variance; Anti-Arrhythmia Agents; Chi-Square Distribution; Defibrillators, Implant | 2005 |
Sustained torsade de pointes occurring early during oral sotalol therapy for atrial fibrillation recurrence prophylaxis in a patient without heart disease.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Humans; Middle Aged; Recu | 2005 |
Rate of conversion and recurrence after sotalol treatment in patients with direct current-refractory atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Case-Control Studies; Electric Countershock; Fema | 2006 |
[Conversion in sinus rhythm].
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Diagnosis, Differential; Dose-Response Relationship, Dr | 2006 |
Differential effects of sotalol and metoprolol on induction of paroxysmal supraventricular tachycardia.
Topics: Adult; Aged; Atrioventricular Node; Female; Humans; Male; Metoprolol; Middle Aged; Recurrence; Sotal | 1984 |
Sotalol for atrial tachycardias after surgery for congenital heart disease.
Topics: Administration, Oral; Adult; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Bradycardi | 1997 |
Patient characteristics and underlying heart disease as predictors of recurrent atrial fibrillation after internal and external cardioversion in patients treated with oral sotalol.
Topics: Administration, Oral; Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershoc | 1997 |
Factors influencing long term persistence of sinus rhythm after a first electrical cardioversion for atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Digoxin; Electric Countershock; Female; Fol | 1998 |
Long-term reproducibility of electrophysiologically guided therapy with sotalol in patients with ventricular tachyarrhythmias.
Topics: Anti-Arrhythmia Agents; Electrophysiology; Female; Follow-Up Studies; Humans; Male; Middle Aged; Rec | 1999 |
Incidence and modes of onset of early reinitiation of atrial fibrillation after successful internal cardioversion, and its prevention by intravenous sotalol.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrilla | 1999 |
Intravenous sotalol decreases transthoracic cardioversion energy requirement for chronic atrial fibrillation in humans: assessment of the electrophysiological effects by biatrial basket electrodes.
Topics: Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Combined Modality Thera | 2000 |
[Paroxysmal atrial fibrillation].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Electric Countershock; F | 2000 |
Sotalol in the treatment of fetal dysrhythmias.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Follow-Up Studies; Humans; Hydrops Fetalis; Inf | 2000 |
The frequency analysis of signal-averaged ECG of P wave as predictor of efficacy of class III antiarrhythmic drugs to maintain sinus rhythm in recurrent idiopathic atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Female; Humans; | 2001 |
Global distribution of atrial ectopic foci triggering recurrence of atrial tachyarrhythmia after electrical cardioversion of long-standing atrial fibrillation: a bi-atrial basket mapping study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; | 2001 |
Flecainide and sotalol: a new combination therapy for refractory supraventricular tachycardia in children <1 year of age.
Topics: Anti-Arrhythmia Agents; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Therapy, Com | 2002 |
[Atrial fibrillation successfully converted. A new standard in the prevention of recurrence?].
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Calcium Ch | 2001 |
Atrial fibrillation recurrence after internal cardioversion: prognostic importance of electrophysiological parameters.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Electro | 2002 |
Sotalol-induced torsade de pointes: management with magnesium infusion.
Topics: Aged; Amiodarone; Atrial Fibrillation; Dose-Response Relationship, Drug; Electrocardiography, Ambula | 1992 |
Serial antiarrhythmic drug treatment to maintain sinus rhythm after electrical cardioversion for chronic atrial fibrillation or atrial flutter.
Topics: Actuarial Analysis; Aged; Amiodarone; Analysis of Variance; Atrial Fibrillation; Atrial Flutter; Chr | 1991 |
Sotalol in patients with life-threatening ventricular tachyarrhythmias.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Coronary Angiography; Coronary Disease; Electric Stimulation; E | 1990 |
Safety and efficacy of sotalol in patients with drug-refractory sustained ventricular tachyarrhythmias.
Topics: Cardiac Pacing, Artificial; Female; Heart Ventricles; Humans; Male; Middle Aged; Recurrence; Sotalol | 1990 |
Therapy of refractory symptomatic atrial fibrillation and atrial flutter: a staged care approach with new antiarrhythmic drugs.
Topics: Adult; Aged; Atrial Fibrillation; Atrial Flutter; Data Interpretation, Statistical; Drug Administrat | 1990 |
Inadvertent catheter-induced right bundle branch block in a patient with preexistent left bundle branch block and recurrent macroreentrant ventricular tachycardia.
Topics: Aged; Amiodarone; Bundle-Branch Block; Cardiac Catheterization; Electric Stimulation; Electrocardiog | 1989 |
Low-dose oral sotalol for monomorphic ventricular tachycardia: effects during programmed electrical stimulation and follow-up.
Topics: Administration, Oral; Adult; Aged; Cardiac Pacing, Artificial; Chronic Disease; Drug Evaluation; Ele | 1989 |
Usefulness of sotalol in suppressing ventricular tachycardia or ventricular fibrillation in patients with healed myocardial infarcts.
Topics: Aged; Coronary Disease; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Middle Aged; M | 1989 |
Clinical experience with sotalol in patients with drug-refractory ventricular arrhythmias.
Topics: Administration, Oral; Arrhythmias, Cardiac; Drug Resistance; Electric Countershock; Electrophysiolog | 1989 |
Oral sotalol in neonatal supraventricular tachycardia.
Topics: Humans; Infant, Newborn; Recurrence; Sotalol; Tachycardia, Supraventricular | 1988 |